ClinicalTrials.gg
RecruitingNCT07166822Updated Sep 10, 2025

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

An interventional study of Experimental group using BumptUp mobile exercise app in Cardiovascular (CV) Risk and Exercise, sponsored by Old Dominion University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Old Dominion University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this study is to determine the effectiveness of a mobile exercise app in improving cardiovascular health and motivation to exercise in pregnant women who are healthy, in their 2nd trimester, between 18-45 years age, and do not do exercise currently. The aims of this study are determine i) the effect of a mobile app (BumptUp) to increase motivation to exercise as assessed by questionnaire, and ii) the changes may occur in cardiovascular health outcomes such as increased percent Flow-Mediated Dilation (FMD), Heart Rate Variability (HRV), and decreased Pulse Wave Velocity (PWV) over an 8-week period of intervention. Researchers will compare this to pregnant women who are healthy, in their 2nd trimester, between 18-45 years age, and who will not be using the mobile app (BumptUp) for exercise. Participants who are in the experimental group will be given access to the mobile app (BumptUp) for 8 weeks. Both the control and experimental group will visit the lab for their baseline measurements (study visit 1), followed by two visits at 4 weeks (study visit 2) and 8 weeks (study visit 3) to have their heart rate variability, arterial stiffness (PWV), and vascular function (FMD) assessed. At each study visit, blood pressure, heart rate, height, and weight will also be measured. Additionally, at all three study visits, participants will fill out a questionnaire to determine motivation to exercise.

02

Conditions studied

  • Cardiovascular (CV) Risk
  • Exercise

Browse trials for

Keywords

  • pregnant
  • cardiovascular
  • mobile app
  • exercise
03

In context

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

Old Dominion University is the lead sponsor of 27 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-45 years.
  • Pregnant women who are 20-24 weeks pregnant at enrollment
  • Sedentary, as defined by completing less than 90 minutes of exercise each week.
  • Generally healthy, uncomplicated pregnancies.
  • Free of physical limitations that may interfere with alterations in daily physical activity levels.
  • Single gestation.
  • Have a smartphone
  • Under the routine medical care of an obstetrician or certified nurse midwife during their current pregnancy.
  • Women speaking English.

Exclusion criteria

Exclusion Criteria:

  • Physician diagnosed cardiovascular/ vascular complications (heart disease, high blood pressure, Raynaud's phenomenon etc.)
  • Physician diagnosed metabolic diseases (diabetes, hypothyroidism)
  • Musculoskeletal injuries (broken bones, back pain, ankle sprain, muscle pull, etc.)
  • Medications that may impact blood vessel function such as hypertension medication (Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker, beta blocker), lipid lowering agents (statins), Nitrates, , etc.
  • Complications associated with pregnancy that would be exacerbated by exercise such as lung disease, persistent spotting/bleeding or Placental Previa, premature labor, ruptured membranes, evidence of intrauterine growth restriction, pregnancy induced hypertension or pre-eclampsia, uncontrolled epileptic fits/seizures.
  • Smoking within the previous 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental arm who will use the BumptUp mobile exercise app

    This group will have access to "BumptUp" mobile exercise app and will be provided with an educational brochure (Exercise during pregnancy)

    Behavioral: Experimental group using BumptUp mobile exercise app

  • No intervention
    Control group

    This group will have no access to "BumptUp" mobile exercise app and will only be provided with an educational brochure (Exercise during pregnancy)

Interventions

  • BehavioralExperimental group using BumptUp mobile exercise app

    This BumptUp app has been developed specifically for pregnancy with safety and screening feature. This intervention will be unique since the researchers will evaluate the cardiovascular health outcomes following the 8 weeks of intervention.

    Also known as: BumptUp app

06

What researchers measure

Primary outcomes

  1. Flow mediated dilation

    The cardiovascular health via flow mediated dilation (% change from baseline) will be assessed

    Time frame: 8 weeks of intervention period

Secondary outcomes

  1. Arterial stiffness

    Cardiovascular health will be measured via arterial stiffness determining pulse wave velocity (m/sec)

    Time frame: 8 weeks

Other outcomes

  1. Heart rate variability

    Cardiovascular health will be measured via heart rate variability (msec).

    Time frame: 8 weeks

  2. motivation to exercise

    Motivation to exercise will be measured via questionnaire

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Aug 2027, 22 months later.

Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 22 months is above that.

Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 10, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2028
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07166822
Lead sponsor
Old Dominion University
Responsible party
Leryn Reynolds (Associate Professor, Old Dominion University) — Principal investigator
First posted
Sep 10, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Sep 10, 2025

Study contacts

Principal Investigator, PhD
Contact
lreynold@odu.edu
757-683-4974

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion